Intermittent Fasting Types Compared: 16:8, 5:2, OMAD, ADF

Eighteen Hours Changes Everything

Around the 18-hour fasting mark, liver glycogen stores deplete enough to trigger a measurable rise in blood ketone bodies — a metabolic shift researchers call "metabolic switching." Below that threshold, insulin remains elevated enough to suppress fat oxidation. This single physiological inflection point explains why popular protocols are structured the way they are, and why a 12-hour overnight fast produces fundamentally different metabolic outcomes than a 16-hour one.

Four Protocols, Four Different Demands

Every intermittent fasting method imposes a different burden on adherence, social life, and physiology. Understanding what each actually requires prevents the common mistake of choosing a protocol based on popularity rather than personal fit.

16:8: The Entry Point

The 16:8 protocol is the most studied and most practiced variant. Participants skip breakfast, eat between roughly noon and 8 p.m., and fast overnight. A 2020 randomized trial published in Cell Metabolism by Sutton et al. found early time-restricted eating (6-hour window, 7 a.m.–3 p.m.) improved insulin sensitivity in men with prediabetes independent of weight loss — suggesting the timing of the window matters, not just its length. However, a 2022 TREAT trial (Lowe et al., New England Journal of Medicine) found 16:8 produced no significant weight-loss advantage over unrestricted eating when calories were not explicitly controlled. The honest summary: 16:8 works best when it incidentally reduces intake.

5:2: Krista Varady's Landmark Research

University of Illinois Chicago researcher Krista Varady has published more randomized controlled trials on alternate-day and modified fasting than any other investigator. Her 2013 comparison of 5:2 against continuous caloric restriction found equivalent 8-week weight loss (~5 kg) and equivalent improvements in LDL cholesterol and triglycerides. The key finding: adherence on the two fasting days was the primary predictor of success. Participants who ate closer to 500 kcal on fast days (not 800 or 1,000) achieved results comparable to daily caloric restriction without the daily monotony.

OMAD: Maximum Switch, Maximum Risk

OMAD condenses all daily calories into a single meal. Ketone levels. Rise sharply. But the protocol carries a real protein-distribution problem: muscle protein synthesis requires leucine thresholds (~2.5–3 g leucine per meal), and consuming an entire day's protein in one sitting does not replicate the anabolic stimulus of three distributed meals. A 2021 review in Nutrients concluded that while OMAD achieves greater fat loss acutely, it may accelerate lean mass loss relative to 16:8 when protein is not carefully optimized.

Alternate-Day Fasting

ADF alternates a "feast day" (ad libitum eating) with a "fast day" (~500 kcal). Varady's 2019 CALERIE-adjacent work found ADF reduced body weight by 6% over 24 weeks versus 5.3% for continuous restriction — a modest but real difference. Critically, ADF also produced a 20–35% reduction in fasting insulin levels, which some cardiometabolic researchers argue matters more than the weight number itself.

The CALERIE Trial: Caloric Restriction in Humans

The Comprehensive Assessment of Long-Term Effects of Reducing Intake of Energy (CALERIE) phase 2 trial randomized 218 non-obese adults to 25% caloric restriction for 2 years. Published in The Lancet Diabetes & Endocrinology (2015), participants achieved only 11.9% caloric restriction on average but still showed a 14.3% extension of estimated lifespan markers (based on aging biomarkers including HOMA-IR, blood pressure, and cholesterol). Intermittent fasting was not the intervention — but the trial established that sustainable caloric restriction in healthy humans produces measurable physiological benefits.

The Muscle Loss Debate

No topic generates more disagreement in fasting research. The concern: prolonged fasting raises cortisol and reduces mTOR activity, both of which suppress muscle protein synthesis.

• A 2011 Ramadan fasting study (Moro et al.) found no significant lean mass loss in resistance-trained men using 16:8 for 8 weeks while maintaining protein intake at 1.8 g/kg/day.
• A 2020 meta-analysis in Obesity Reviews (Cioffi et al.) found intermittent fasting and continuous restriction produced identical lean mass loss when total protein was matched.
• OMAD and ADF show greater lean mass loss risk in studies where protein is not controlled, particularly in older adults.

The consensus position among exercise scientists: protein intake (≥1.6 g/kg/day) and resistance training override fasting protocol as predictors of muscle preservation.

Choosing by Biomarker, Not Trend

• People with type 1 diabetes, eating disorders, or pregnancy should not attempt any fasting protocol without direct physician supervision.
• Medications including metformin and SGLT-2 inhibitors require dose timing adjustments during fasting windows.
• Women appear more sensitive to prolonged fasting-induced cortisol spikes — some research suggests 14:10 may outperform 16:8 for this group.

Metabolic Switching Is the Mechanism, Not the Goal

Fasting researchers including Mark Mattson at the National Institutes of Health have argued that metabolic switching — the periodic shift from glucose to ketone metabolism — is itself the therapeutic signal. Not weight loss. Not caloric deficit. The switch itself may upregulate BDNF (brain-derived neurotrophic factor), improve mitochondrial biogenesis, and reduce systemic inflammation markers including IL-6 and CRP. Human trial data on these endpoints remains preliminary, but the mechanistic case is increasingly robust.

This article is for informational purposes only. Consult a qualified healthcare professional.